<!DOCTYPE html>
<html>
	<head>
		<meta charset="UTF-8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title>Osteomyelitis: Upper Extremities</title>
		<link href="/index.css" type="text/css" rel="stylesheet">
		<script src="//code.jquery.com/jquery-1.10.2.js"></script>
		<script>
			$(function(){
				$("#header").load("/header.html");
				$("#footer").load("/footer.html");
			});
		</script>
		<script>
			function navDrop() {
				var x = document.getElementById('navlinks');
				if (x.style.display === 'flex') {
					x.style.display = 'none';
				} else {
					x.style.display = 'flex';
				}
			}
		</script>
	</head>
	<body>
		<header id="header"></header>
		<div class="spacer"></div>
		<div class="main">
			<h1>Osteomyelitis</h1>
			<h2 id="anatomical-approach">Anatomical Approach</h2>
			<h3 id="upper-extremities">Upper Extremities</h3>
			<p>Most common causes:</p>
			<ul>
				<li><p>Contiguous extension of a focal source of infections related to traumatic injury</p></li>
				<li><p>Acute septic arthritis of the joint</p></li>
				<li><p>Pathological fractures</p></li>
			</ul>
			<figure>
				<!-- <p class="placeholder"><em>(Need a small box for diagnostic approach with bone biopsy, MRI/CT of extremity (always obtain a comparative study over time of the joint and the bone) ((reminder to put images of comparative radiographs)), bone cultures and stains (aerobic, anaerobic, AFB, fungal), ESR, CRP, CMP, CBC with differential counts.</em></p> -->
				<p class="placeholder">Diagnostic approach figure under construction.</p>
			</figure>
			Empiric antimicrobial management after bone cultures are obtained by the following means.
			</ul>
			<p id="for-contiguous-osteomyelitis">For contiguous osteomyelitis:</p>
			<ul>
				<li><p>Vancomycin plus Piperacillin-Tazobactam </p></li>
				<li><p>(If there is no concern for anaerobic infection <strong>Vancomycin and cefepime</strong> is an acceptable regimen)</p></li>
			</ul>
			<p id="for-hematogenous-osteomyelitis">For hematogenous osteomyelitis:</p>
			<ul>
			<li><p>Vancomycin plus (ceftriaxone, ceftazidime or cefepime).</p></li>
			<li><p>Acceptable regimens include <strong>Vancomycin plus Piperacillin-Tazobactam</strong>.</p></li>
			</ul>
			<p>Empiric antibiotics should always be based on appropriate clinical context of patient’s co-morbid conditions and historical microbiological data.</p>
			<p>For example, an immunocompromised patient who is a gardener, pathogens such as fungal and atypical mycobacterium, fusobacterium should be considered in the differential.</p>
			<p>Deescalate all empiric antibiotic therapy as mentioned above based on culture results and susceptibility tests.</p>
			<p>Selected pathogens for <strong>contiguous osteomyelitis</strong> are:</p>
			<ul>
			<li><p><em>Staphylococcus aureus</em></p></li>
			<li><p>Coagulase-negative staphylococci</p></li>
			<li><p>Gram-negative bacilli</p></li>
			<li><p>Streptococcus species</p></li>
			<li><p><em>Pseudomonas aeruginosa</em> spp.</p></li>
			</ul>
			<p>Selected pathogens for <strong>hematogenous osteomyelitis</strong> are:</p>
			<ul>
			<li><p><em>Staphylococcus aureus</em></p></li>
			<li><p>Group A Streptococcus</p></li>
			<li><p>Enteric gram-negative bacilli</p></li>
			<li><p>Salmonella species (especially among patients with sickle cell disease)</p></li>
			<li><p><em>Kingella kingae</em> (especially children under 4 years of age)</p></li>
			</ul>
			<p>Pathogen-directed therapy (see <strong>Table <a href="#antibiotics" data-reference-type="ref" data-reference="antibiotics">1</a></strong>):</p>
			<ul>
			<li><p>MSSA—Nafcillin or Cefazolin</p></li>
			<li><p>MRSA—Vancomycin</p></li>
			<li><p>Gram-negative bacilli—Ciprofloxacin or Levofloxacin</p></li>
			<li><p>Streptococcus spp.—Penicillin or Ceftriaxone</p></li>
			<li><p>Pseudomonas (if susceptible)—Ciprofloxacin or Levofloxacin</p></li>
			<li><p>Salmonella spp.—Ceftriaxone</p></li>
			<li><p><em>Kingella kingae</em>—Ceftriaxone plus anti-staphylococcal agent (<em>defer this to pediatric section</em>)</p></li>
			</ul>
			<hr/>
			<div class="table" id="antibiotics">
				<table>
					<caption><strong>Table 1.</strong> Suppression of osteomyelitis or prothetic joint infection in adults: Oral antibiotic regimens.* (<a href="https://www.uptodate.com/contents/image/print?topicKey=114350&search=nonvertebral%20osteomyelitis&source=outline_link&imageKey=ID%2F119913">UpToDate</a>)</caption>
					<thead>
						<tr><th>Infectious agent</th><th>Antibiotic regimen<sup>&para;</sup></th><th>Dosing</th></tr>
					</thead>
					<tbody>
						<tr><td rowspan="5"><strong>Staphylococci, methicillin susceptible</strong></td><td colspan="2"><strong>One of the following:</strong></td></tr>

						<tr><td>Cefadroxil</td><td>500 to 1000 mg twice daily</td></tr>
						<tr><td>Cephalexin</td><td>500 mg 3 or 4 times daily, or 1000 mg 2 or 3 times daily</td></tr>
						<tr><td>Dicloxacillin</td><td>500 mg 3 or 4 times daily</td></tr>
						<tr><td>Flucloxacillin</td><td>500 mg 3 or 4 times daily</td></tr>
						<tr><td rowspan="5"><strong>Staphylococci, methicillin resistant</strong><sup>Δ</sup></td><td colspan="2"><strong>One of the following:</strong></td></tr>
						<tr><td>Trimethoprim-sulfamethoxazole</td><td>1 double-strength tablet twice daily</td></tr>
						<tr><td>Doxycycline</td><td>100 mg twice daily</td></tr>
						<tr><td>Minocycline</td><td>100 mg twice daily</td></tr>
						<tr><td>Clindamycin</td><td>600 mg 3 times daily</td></tr>
						<tr><td rowspan="4"><strong>Gram-negative organisms</strong></td><td colspan="2"><strong>One of the following:</strong></td></tr>
						<tr><td>Trimethoprim-sulfamethoxazole</td><td>1 double-strength tablet twice daily</td></tr>
						<tr><td>Ciprofloxacin<sup>◊</sup></td><td>500 mg twice daily</td></tr>
						<tr><td>Levofloxacin<sup>◊</sup></td><td>500 mg once daily</td></tr>
						<tr><td rowspan="3"><strong>Penicillin-sensitive streptococci and enterococci</strong></td><td colspan="2"><strong>One of the following:</strong></td></tr>
						<tr><td>Amoxicillin</td><td>500 mg 2 to 3 times daily</td></tr>
						<tr><td>Penicillin V K</td><td>500 mg 2 to&nbsp;4 times daily</td></tr>
						<tr><td rowspan="3"><strong><em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em></strong></td><td colspan="2"><strong>One of the following:</strong></td></tr>
						<tr><td>Amoxicillin</td><td>500 mg 2 to 3 times daily</td></tr>
						<tr><td>Penicillin V K</td><td>500 mg 2 to 3 times daily</td></tr>
					</tbody>
				</table>
				<p>The doses recommended above are intended for adults with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency. Refer to the Lexicomp drug-specific monographs for renal dose adjustments.</p>
				<p>PJI: Prosthetic joint infection.<br>	
					* Initial treatment of PJI consists of definitive antibiotic therapy (refer to the separate UpToDate table); suppressive therapy is warranted only for individuals with retained hardware and/or necrotic bone not amenable to complete debridement. The optimal duration of oral suppressive antibiotic therapy is uncertain. Refer to the UpToDate topic on the treatment of PJI for further discussion.<br>	
					&para; The choice of antibiotic regimen should be based on susceptibility, as well as patient drug allergies, intolerances, and potential drug-drug interactions or contraindications to a specific agent.<br>	
					&Delta; The agents listed for methicillin-resistant staphylococci may be used for suppression of methicillin-susceptible staphylococci in patients with beta-lactam allergy or intolerance, provided the organism is susceptible.<br>	
					&loz; Ciprofloxacin and levofloxacin have activity against <em>Pseudomonas aeruginosa</em>.</p>
					<p>
					Data from:
						<ol>
							<li>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2013; 56:e1.</li>
							<li>Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis 2015; 61:e26.</li>
						</ol>
					</p>
			</div>
			<hr/>
			<p>Alternative regimens for MRSA and MSSA: Ciprofloxacin plus Rifampin or if susceptible.</p>
			<h4 id="humerus-osteomyeletis">Humerus Osteomyeletis</h4>
			<p>Most common cause is related to either of:</p>
			<ul>
				<li><p>Septic arthritis with or without blood stream infection.</p></li>
				<li><p>Post-traumatic injury complications.</p></li>
			</ul>
			<h5 id="with-retained-hardware">With retained hardware</h5>
			<p>Therapeutic approach will be pathogen-directed (see above) for six weeks, followed by suppressive therapy (see Table).</p>
			<h5 id="without-retained-hardware">Without retained hardware</h5>
			<p>Pathogen-directed (see above) therapy for six weeks. No suppressive therapy needed.</p>
			<h4 id="forearm-osteomyelitis">Forearm Osteomyelitis</h4>
			<p>Same as humerus osteomyelitis.</p>
			<h4 class="unnumbered" id="duration-of-therapy-1">Duration of therapy</h4>
			<p>Six to eight weeks—longer if hardware is retained.</p>
			<ul>
			<li><p>Early hardware infection &lt;4 weeks:</p>
			<ul>
			<li><p>If hardware removed, treat for six weeks.</p></li>
			<li><p>If hardware retained, treat until bony fusion or hardware removal.</p></li>
			</ul></li>
			<li><p>Late infection &gt;4 weeks:</p>
			<ul>
			<li><p>Remove hardware if possible and treat for 6 weeks.</p></li>
			<li><p>Retained hardware, treat for 3–6 months or until hardware removed.</p></li>
			</ul></li>
			</ul>
			<h4 id="hand-osteomyelitis">Hand Osteomyelitis</h4>
			<p>(See SSTI)</p>
			<h5 id="culture-negative-osteomyelitis-of-the-upper-extremities">Culture Negative Osteomyelitis of the Upper Extremities</h5>
			<p>Treatment is based on patient’s microbiological history, hospital anitbiogram, and risk factors of host for MDR pathogens.</p>
		</div>
		<footer id="footer"></footer>
	</body>
</html>